Allakos Reaches Corporate Endpoint with Concentra Acquisition

The independent journey of Allakos as a publicly traded biopharmaceutical firm has concluded following its acquisition by Concentra Biosciences. Shareholders received a final distribution of $0.33 per share, a figure that stands in stark contrast to the stock’s 52-week peak of $1.55. Announced in April 2025, the transaction was finalized by mid-May, with approximately 81% of outstanding shares tendered at the agreed price.

The merger precipitated immediate executive changes. Dr. Robert Alexander stepped down from his role as Chief Executive Officer, accompanied by the departure of Chief Financial Officer Baird Radford. Management authority transferred entirely to Concentra’s leadership team. This transition marks the definitive end for investors:

• Trading Ceased: Read more...